Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dow Chemical to acquire Rohm and Haas

This article was originally published in Scrip

Executive Summary

Dow Chemicalhas reached a definitive agreement to acquire the speciality chemical company Rohm and Haasfor more than $15 billion, to create the world's leading speciality chemicals and advanced materials company. It will pay $78 in cash for each outstanding share, a more than 73% premium to Rohm and Haas's closing share price on July 9th. The move into more high-margin speciality chemicals should help protect Dow from the more cyclical basic chemical sales business, and it described it as a decisive move to transform Dow into an earnings growth company. Rohm and Haas is best known for its paint and electronics materials businesses but its technologies are found in a wide range of industries, including pharmaceuticals. The deal, which has been unanimously approved by the boards of both companies, remains subject to approval by Rohm and Haas shareholders and regulatory approvals.

You may also be interested in...

Another Failure For Biohaven’s Troriluzole

Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.

FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu

The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.

Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit

The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts